ABCL Stock Catalyst: AbCellera Biologics Inc. Announces Positive Phase 2 Results for ABCL635

Aug 10, 2026 · 6:37am ET

The trial demonstrated significant symptom reduction and favorable tolerability.

Max move

+33.6%

High of day $10.01

Sparker timei

6:37am ET

ABCL · Aug 10, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

AbCellera Biologics Inc. (Nasdaq: ABCL) announced positive top-line results from its Phase 2 clinical trial for ABCL635. The trial showed a significant reduction in the frequency and severity of vasomotor symptoms, along with a favorable tolerability profile.

The trial results indicate potential for ABCL635 as a treatment option for vasomotor symptoms. AbCellera plans to further evaluate the data to determine next steps for the drug's development.

As of the latest data, AbCellera has a free float of 205,087,000 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ABCL sparks.

Download Sniper App →

Catch the next ABCL-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →